28 jun: Når lav risiko giver højt afkast
17 jul: Test
29-06-2012 07:30:51

Regulated information - Ageas communicates on revised total number of issued shares

Relateret indhold
26 okt - 
Euroinvestor 9M: Nedskrivninger giver underskud
26 okt - 
Aktier/åbning: DSV og Nordea tager top og bund i vaklen..
26 okt - 
Aktier/tendens: DSV og Nordea sætter liv i ellers afven..

Following the cancellation of the shares bought back during the buy-back programme launched in August 2011, the total number of issued shares (the 'denominator') has fallen to 2,431,212,726.

At the end of January Ageas completed its share buy-back programme for a total amount of EUR 250 million, representing 192,168,091 shares. The General Meetings of Shareholders already approved at the end of April 2012 the cancellation of these shares but the Dutch law allows for a 2 month period of objection. As this period is now at an end, the shares have been cancelled, and as a result, the total amount of issued shares is reduced to 2,431,212,726. As from today, this number will be used to calculate percentage shareholdings.

As a further consequence, and in accordance with the rules on financial transparency, Ageas confirms that its interest fell below the threshold of 3% on 29 June 2012.

The transparency information is available on the Ageas website under "Investor relations - The share - Transparency requirements" (http://www.ageas.com/en/Pages/transparency_requirements.aspx). 

Ageas is an international insurance company with a heritage spanning more than 180 years. Ranked among the top 20 insurance companies in Europe, Ageas has chosen to concentrate its business activities in Europe and Asia, which together make up the largest share of the global insurance market. These are grouped around four segments: Belgium, United Kingdom, Continental Europe and Asia and served through a combination of wholly owned subsidiaries and partnerships with strong financial institutions and key distributors around the world. Ageas operates successful partnerships in Belgium, UK, Luxembourg, Italy, Portugal, Turkey, China, Malaysia, India and Thailand and has subsidiaries in France, Hong Kong and UK. It is the market leader in Belgium for individual life and employee benefits, as well as a leading non-life player, through AG Insurance, and in the UK, it has a strong presence as the third largest player in private car insurance and the over 50's market. It employs more than 13,000 people and has annual inflows of more than EUR 17 billion.

MEDIA CONTACT

+32 (0)2 557 57 37 / +32 (0) 479 79 50 02

INVESTOR RELATIONS

Brussels

+32 (0)2 557 57 33

Utrecht

+31 (0)30 252 53 05

Ageas

Rue du Marquis 1 - 1000 Brussels - Belgium

Archimedeslaan 6 - 3584 BA Utrecht - The Netherlands

www.ageas.com

Notification

Pdf version press release


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Ageas via Thomson Reuters ONE

HUG#1622732

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Aktier/tendens: Ørsted kan ryge til vejrs i ellers haltende åbning

14-12-2017 08:19:22
En forventet stigning til energiselskabet Ørsted kan næppe ændre ved det samlede billede for det danske aktiemarked, som torsdag morgen ser ud til at starte let haltende og måske med en lille pil nedad. Det sker oven på en onsdag, hvor det ledende C20 cap-indeks gik ned på grund af tekniske problemer og hen over eftermiddagen ikke blev opdateret. Senere blev det dog opgjort til at være lukket i 11..

Harboes H1: Dårligt sommervejr ramte både omsætningen og indtjeningen

13-12-2017 15:48:19
Dårligt sommervejr i Nordeuropa ramte både omsætningen og indtjeningen hos Harboes Bryggeri, der har haft et markant dårligere første halvår af det skæve regnskabsår 2017/18 sammenlignet med for et år siden.Nettoomsætningen fra maj til udgangen af oktober faldt til 696,4 mio. kr. mod 744,6 mio. kr. i samme periode året forinden, fremgår det af halvårsregnskabet for 2017/18 onsdag eftermiddag.På de..

Novo-rival spår effekt af ugentligt GLP-1 på linje med Ozempics

13-12-2017 13:30:09
Novo Nordisks store franske rival Sanofi forudser, at dens ugentlige GLP-1-analog, Efpeglenatid, har en effekt på langtidsblodsukkeret, der er på linje Novos nye ugentlige diabetes 2-middel Ozempic, som tilhører samme lægemiddelklasse.Det fremgår af en præsentation under et analytikerarrangement onsdag, hvor Sanofi fremlægger sin forsknings- og udviklingsstrategi for de kommende år.Sanofi indledte..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas får sin største ordre nogensinde i Indien - NY
2
Vestas rykker nærmere kæmpekontrakter i New Mexico og Texas
3
Onsdagens aktier: Genmab endnu engang til bunds i negativt marked
4
Aktier: C20 og kompagni lagt ned i timevis af teknisk uheld - NY4
5
Aktier/tendens: Ørsted kan ryge til vejrs i ellers haltende åbning

Relaterede aktiekurser

Ageas 41,60 -0,1% Fald i aktiekurs
Euroinvestor.com A/S 9,85 -1,5% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
14. december 2017 10:59:46
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171124.1 - EUROWEB5 - 2017-12-14 10:59:46 - 2017-12-14 10:59:46 - 1 - Website: OKAY